Long-term evaluation of ProACT therapy for stress urinary incontinence in men
Official title: Post Approval Study of the ProACT™ Adjustable Continence Therapy for Men
Run by Uromedica · NCT03767595 · Data updated 2026-11-12
This study is testing how well the ProACT therapy works for men with stress urinary incontinence after prostate surgery and checking for any long-term issues with the treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years and up |
| Sex | Men only |
| Enrollment | 145 (estimated) |
| Sponsor | Uromedica Industry-sponsored |
| Drugs / interventions | radiation |
| Locations | 14 sites (Los Angeles, California and 13 other locations) |
| Status | Recruiting |
| Started | February 19, 2019 |
| Main results expected | December 31, 2031 |
| Study ends | December 31, 2031 |
| Registry record updated | October 6, 2026 |
| Trial ID | NCT03767595 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are men aged 50 and older who have stress urinary incontinence and have previously undergone prostate surgery.
✕Probably not a fit
Patients with active urogenital malignancies or those who do not meet the inclusion criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The ProACT Post Approval Study is a five-year, prospective, open-label, multi-center evaluation aimed at assessing the long-term effects of ProACT Adjustable Continence Therapy in men who have undergone prostate surgery. This study will monitor the incidence of urethral stricture and device erosion following ProACT implantation, as well as the impact of this treatment on clinical outcomes after subsequent therapies for stress urinary incontinence. Participants will be required to undergo annual follow-up interviews to track their progress and any complications over the study period.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term safety and efficacy of ProACT therapy, potentially improving treatment options for men suffering from stress urinary incontinence.
How similar studies have gone: While this study builds on existing knowledge of ProACT therapy, it specifically focuses on long-term outcomes, which may provide new insights into its effectiveness and safety.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Subject is a male of at least 50 years of age.
2. Subject demonstrates stress urinary incontinence.
3. Subject has undergone a radical prostatectomy, transurethral resection of the prostate, or other prostate surgery.
4. Subject is willing and able to undergo surgical implantation of ProACT devices.
5. Subject is willing and able to comply with study-required
follow-up activities, including annual telephonic follow -up interviews, for a period of 5 years from their date of initial implantation. This includes compliance even after possible explant of ProACT devices and/or possible implantation of subsequent therapies.
6. Subject is willing and able to sign the approved informed consent.
7. Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests).
8. Subject has a negative urine culture.
9. Subject has no known urogenital malignancy, other than previously treated prostate cancer.
10. Subject meets ONE of the following criteria:
1. Baseline Prostate-Specific Antigen (PSA) of less than or equal to 2.5ng/mL;
2. Baseline PSA \> 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater than or equal to 25% of total PSA;
11. Physician determines subject to be a suitable surgical candidate.
Exclusion Criteria:
1. Subject has an existing urethral stricture, a history of any urethral strictures, or has ever had a urethrotomy.
2. Subject has undergone prostate surgery or any anti-incontinence surgery within the last 12 months.
3. Subject has an artificial urinary sphincter or any components of a previously implanted artificial urinary sphincter in vivo.
4. Subject has undergone radiation therapy in the prostatic area within the last 12 months.
5. Subject has untreated or unsuccessfully treated detrusor instability or over-activity.
6. Subject has an atonic bladder.
7. Subject had, presently has, or is suspected of having bladder cancer.
8. Subject has untreated or unsuccessfully treated bladder stones.
9. Subject has detrusor sphincter dyssynergia.
10. Subject has known hemophilia or a bleeding disorder.
11. Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or respiratory arrest).
12. Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as indicated by an A1c test result of = 6.5%.
Where it's running
-
University of Southern California
Los Angeles, California, United States Recruiting -
Sutter Health
Santa Barbara, California, United States Recruiting -
University of Colorado
Denver, Colorado, United States Recruiting -
University of Florida
Gainesville, Florida, United States Recruiting -
Urological Research Network Corp
Hialeah, Florida, United States Recruiting -
Emory University
Atlanta, Georgia, United States Recruiting
Show 8 more locations
-
University of Kansas Medical Center
Kansas City, Kansas, United States Recruiting -
University of Michigan
Ann Arbor, Michigan, United States Recruiting -
CentraCare- St. Cloud
Saint Cloud, Minnesota, United States Recruiting -
CHI Health Research
Omaha, Nebraska, United States Recruiting -
Lehigh Valley Health Network
Allentown, Pennsylvania, United States Recruiting -
Allegheny Health Network
Pittsburgh, Pennsylvania, United States Recruiting -
Urology Partners of North Texas Research Institute
Arlington, Texas, United States Recruiting -
DHR Health Institute for Research and Development
McAllen, Texas, United States Recruiting
Study contacts
- Study coordinator: Matt Kelly, PhD
- Email: usmtk@coloplast.com
- Phone: 6124698882
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
See if increasing running cadence helps stress urinary incontinence in parous runners
This study tests whether increasing running cadence by about 10% for eight weeks can reduce stress urinary incontinence symptoms in parous women who run regularly and own a Garmin watch.
-
Prophylactic antibiotics to reduce post-procedure UTIs after urethral bulking
We’re testing whether giving a preventive antibiotic at the time of urethral bulking can lower the chance of a urinary tract infection after the procedure for women with stress or mixed urinary incontinence.
-
Evaluating the impact of different mesh widths in surgery for urinary incontinence
This study is testing whether using a wider surgical mesh during surgery for urinary incontinence in women can lead to better results and fewer problems.
-
Evaluating postoperative activity restrictions after midurethral sling placement
This study is testing whether patients who have had a midurethral sling procedure for stress urinary incontinence do better with strict activity limits or no limits after surgery.
-
Comparing two procedures for treating stress urinary incontinence during vaginal prolapse repair
This study is testing whether a new type of surgery or an injection is better for helping women with stress urinary incontinence during vaginal prolapse repair.
-
Effectiveness and safety of shorter tapes for urinary incontinence
This study looks at whether shorter surgical tapes for treating urinary incontinence in women can improve their quality of life and have fewer complications compared to longer tapes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.